每经记者:林姿辰每经编辑:黄胜3月11日,礼来宣布计划未来十年累计投资30亿美元,全面扩展在华供应链产能,打造口服固体制剂本土生产与供应体系,着力布局首个申报注册的口服小分子GLP-1受体激动剂Orforglipron的生产能力。同时,公司宣布与康龙化成达成战略合作,拟投2亿美元支持其技术建设。11日,礼来执行副总裁兼生产运营总裁贺安德(Edgardo Hernandez)告诉《每日经济新闻》记者...
Source Link每经记者:林姿辰每经编辑:黄胜3月11日,礼来宣布计划未来十年累计投资30亿美元,全面扩展在华供应链产能,打造口服固体制剂本土生产与供应体系,着力布局首个申报注册的口服小分子GLP-1受体激动剂Orforglipron的生产能力。同时,公司宣布与康龙化成达成战略合作,拟投2亿美元支持其技术建设。11日,礼来执行副总裁兼生产运营总裁贺安德(Edgardo Hernandez)告诉《每日经济新闻》记者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.